The newly discovered irreversible HDAC6 inhibitor, phenylsulfonylfuroxan-based hydroxamate 4, has superior anti-multiple myeloma activity compared to ACY-241, an HDAC6 inhibitor in clinical trials [194]. This evidence concerns the gene HDAC6 and plasma cell myeloma.